Your browser doesn't support javascript.
Long-term adverse events of three COVID-19 vaccines as reported by vaccinated physicians and dentists, a study from Jordan and Saudi Arabia.
Dar-Odeh, Najla; Abu-Hammad, Osama; Qasem, Farah; Jambi, Safa; Alhodhodi, Aishah; Othman, Ahmad; Abu-Hammad, Abdalla; Al-Shorman, Hisham; Ryalat, Sukaina; Abu-Hammad, Shaden.
  • Dar-Odeh N; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia.
  • Abu-Hammad O; School of Dentistry, University of Jordan, Amman, Jordan.
  • Qasem F; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia.
  • Jambi S; School of Dentistry, University of Jordan, Amman, Jordan.
  • Alhodhodi A; Department of Obstetrics and Gynecology, Istishari Hospital, Amman, Jordan.
  • Othman A; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia.
  • Abu-Hammad A; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia.
  • Al-Shorman H; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia.
  • Ryalat S; School of Medicine, University of Jordan, Amman, Jordan.
  • Abu-Hammad S; Faculty of Dentistry, Jordan University of Science and technology, Irbid, Jordan.
Hum Vaccin Immunother ; 18(1): 2039017, 2022 12 31.
Article in English | MEDLINE | ID: covidwho-1730547
ABSTRACT
Assessment of safety of COVID-19 vaccines is an ongoing process. This study aims to explore long-term adverse events reported by physicians and dentists who received at least two COVID-19 vaccine doses. A group of physicians and dentists were invited to complete a validated questionnaire that was composed of items on socio-demographics, medical history, administered vaccines, and long-term adverse events (LTAE). Data of a total of 498 practitioners were included. Age ranged from 22 to 71 years (mean age= 35.75 ± 11.74) with a female majority (N = 348, 69.9%). The most frequently administered vaccines were Pfizer-BioNtech, Sinopharm and AstraZeneca vaccines. A total of 80 (16.0%) participants reported LTAEs which were mainly fatigue, menstrual disturbances, myalgia, arthralgia, dizziness, and headache (N = 32, 15, 8, 6, 4, and 4, respectively). There was no statistically significant association between LTAEs and age, gender, or medical history (P > .05). The collective symptoms of fatigue, myalgia, arthralgia, dizziness, and headache were significantly associated with Sinopharm vaccine (P = .04). This was further confirmed by general linear multivariate model analysis. Less than 20% of COVID-19 vaccine recipients may complain of LTAEs that are mostly fatigue-related. It seems that factors such as age, gender, and medical status play a negligible role in development of these AEs. On the other hand, Sinopharm vaccine showed the highest significant association with these AEs followed by AstraZeneca vaccine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Physicians / COVID-19 Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Hum Vaccin Immunother Year: 2022 Document Type: Article Affiliation country: 21645515.2022.2039017

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Physicians / COVID-19 Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Hum Vaccin Immunother Year: 2022 Document Type: Article Affiliation country: 21645515.2022.2039017